A prosthesis for a synovial joint arthroplasty within a human body is provided. The prosthesis includes a first prosthetic component, the first prosthetic component including a first surface and the first prosthetic component being formed of a copolymer elastomer compound, the copolymer elastomer compound including a thermoplastic elastomer, a plurality of long glass fibers, the long glass fibers being randomly dispersed throughout the thermoplastic elastomer to improve surface fatigue life and inhibit surface crack propagation to the prosthesis and improve wear resistance of the prosthesis, a number of the plurality of long glass fibers protruding outward from the first surface of the first prosthetic component; a second prosthetic component, the second prosthetic component including a second surface, the second surface of the second prosthetic component positioned proximate the first surface of the first prosthetic component to engage the plurality of long glass fibers protruding from the first surface of the first prosthetic component allowing the second surface of the second prosthetic component to slide relative to the first surface of first prosthetic component while contacting the plurality of long glass fibers protruding outward from the first surface of the first prosthetic component, a gap, the gap created by the voids between the second surface of the second prosthetic component, the first surface of the first prosthetic component and the plurality of long glass fibers that protrude outward from the first surface of the first prosthetic component, the gap further disposed between the first surface of the first prosthetic component and the second surface of the second prosthetic component to allow the passage of fluid between the first surface of the first prosthetic component and the second surface of the second prosthetic component, a first trough, the first trough formed as the plurality of long glass fibers protruding outward from the first surface are forced into the thermoplastic elastomer as the prosthesis is loaded, the first trough positioned proximate each of the plurality of long glass fibers and encasing a perimeter of each of the plurality of long glass fibers.

A joint spacer is provided for treatment of a joint of a human subject, the joint spacer including a pouch having a wall including a dermal graft material. The joint spacer is configured to be inserted into a space of the joint, and is shaped, when the pouch is inserted into the space and filled, to provide mechanical support to the joint. Other embodiments are also described.

The present disclosure relates to manganese dioxide nanoparticles and their use in treatment of oxidative stress and conditions related to or characterized by oxidative stress, including osteoarthritis.

Certain small molecule amino acid phosphate compounds such as phosphoserine and certain multivalent metal compounds such as calcium phosphate containing cements have been found to have improved properties and form an interpenetrating network in the presence of a polymer that contains either an electronegative carbonyl oxygen atom of the ester group or an electronegative nitrogen atom of the amine group as the bonding sites of the polymer surfaces to the available multivalent metal ions.

The invention is a prosthetic joint, for example, knee joint, including a first joint component which is preferably polyetheretherketone containing barium sulphate and a second joint component which is preferably a polyolefin.

A method for implanting a medical device for lubricating a joint in a human body, said method comprising the steps of creating an opening reaching from outside of the human body into the joint, providing an artificial contacting surface to said joint, fixating the artificial contacting surface to the joint, implanting a reservoir in the human body, and lubricating said artificial contacting surface by pressurizing a lubricating fluid contained in said reservoir.

An implant is provided comprising a substrate having one or more nanoceria coatings coated at least partially thereon, wherein the one or more nanoceria coatings comprise surface cerium having a 3+/4+ oxidation state ratio such that the one or more nanoceria coatings exhibit catalase mimetic activity, superoxide dismutase mimetic activity, or both. Methods are provided for forming a nanoceria coating. The coating has nanoceria having a surface cerium 3+/4+ oxidation state ratio such that such that the coating exhibits catalase mimetic activity, superoxide dismutase mimetic activity, or both. Also disclosed is a method of reducing degradation of an implant by placing nanoceria in proximity to a bone-implant interface.

The invention relates to biodegradable, biocompatible materials to promote regeneration of articular surfaces in the temporomandibular joint and, more particularly, to biomaterials and methods for facilitating fibrochondrocyte and chondrocyte growth in in-vitro and in-vivo environments. The materials include magnesium in solid form and polymer. The materials are effective to grow and regenerate fibrochondrocyte and chondrocyte cells, and restore bone cells.

A drug-eluting spacer for temporary implantation in a knee joint includes a femoral component configured to interface with a femur, a tibial tray component having an upper surface, a lower surface, and a shaft extending from the lower surface, the shaft configured to be positioned axially within a tibia, the lower surface configured to interface with the tibia, and a tibial insert component having an upper surface and a lower surface, the lower surface of the tibial insert component configured to engage the upper surface of the tibial tray component, the upper surface of the tibial insert component configured to receive the femoral component in an articulating manner. The femoral component, the tibial tray component, and the tibial insert component carry joint loads when implanted. The drug-eluting spacer is configured to elute a biologically active agent in an amount effective to treat an infection of the knee joint.

The present disclosure relates to a novel sericin-based hydrogel wherein the silk sericin is enzymatically cross-linked for an improved treatment of wound healing, ischemic diseases or cardiovascular diseases, namely chronic wound healing, in particular diabetic wound.